B/BE/19/BVW3 - Summary Notification Information Format (SNIF)

Public information presented according to the provisions of Directive 2001/18/EC
Trial reference: 
A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Noncentral Nervous System Tumors That are Amenable to Direct Injection